LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
+1.87%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$24.35M
MomentumView details →
1D Return
+1.87%
YTD Return
−37.95%
RSI (14)
23.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$24.35M
RSI (14)
23.6
MomentumView details →
1D Return
+1.87%
YTD Return
−37.95%
SummaryUpdated Jun 1, 2026
Lantern Pharma Inc. (NASDAQ:LTRN) is a clinical-stage biotechnology company founded in 2013 and headquartered in Dallas, Texas. The company went public in June 2020 and has positioned itself at the intersection of artificial intelligence and cancer drug development. Lantern Pharma focuses on using AI, machine learning, and genomic data to streamline and accelerate the traditionally lengthy and expensive drug development process, with a particular emphasis on precision oncology treatments.
Similar companies
Latest newsMore news →
Lantern Pharma reported its financial results for the second quarter of 2026 and provided a business update.22d agoLantern Pharma established Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform.33d agoLantern Pharma received a Notice of Allowance from the USPTO for a patent covering biomarker-guided treatment with LP-184 in multiple solid tumor cancers.44d ago